Patient description: The patient is a 15 year old girl with the history of recurrent bilateral headache. The attacks come 2 times or more per week and each episode lasts around a day or a half. The pain is pulsating in quality and severe in intensity, causing trouble in her routine physical activity. The attacks are associated with nausea and photophobia. She recently noticed that that there are more attacks around her menstrual period. She is diagnosed with the migraine headache and is under treatment. She is a high-school student and living with her both parents. She is a book worm and spend her free time in a public library near her home. She is also interested in writing stories and has several short stories in English. She rarely does exercise. Her BMI is 21 with the BP of 100/60. There is nothing remarkable in her physical exam.

Clinical trial eligibility criteria: eligible ages (years): 12.0-17.0,  Migraine Disorders Subject is between 12 and 17 years old at the Screening visit If subject is female, she must have a negative urine pregnancy test at screening, does not plan to become pregnant during the course of the study and agrees to use an acceptable method of birth control (i.e., a method with a failure rate <1% or abstinence) if she is/becomes sexually active Subject has migraine with or without aura (2004 ICHD-II criteria) Subject has history suggestive of typical migraine attacks with duration of about 2 or more hours (untreated, or unsuccessfully treated) Subject has at least 2, but not more than 8, migraine attacks per month in each of the 2 months prior to the Screening visit Subject has at least a 6-month history of moderate to severe migraine attacks, sufficient to establish a definitive diagnosis of migraine Subject is able to distinguish migraine from other headaches (e.g., tension-type headaches) Subject and subject's parent or legal guardian are willing and able to provide informed consent prior to entry into this treatment phase of the study Subject and subject's parent or legal guardian are able to read and write English or Spanish Subject is able to understand and complete the electronic device to report treatment information  Subject is < 75 pounds (33.3kg) Subject has ≥15 headache days per month in total, retinal (ICHD-II 1.4), basilar (ICHD-II 1.26) or hemiplegic migraine (ICHD-II 1.25), or secondary headaches Subject, in the investigator's opinion, is likely to have unrecognized cardiovascular or cerebrovascular disease (See Appendix 1, section 11.1) Subject has uncontrolled hypertension (See Appendix 2, section 11.2) or is taking any angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker Subject has a history of congenital heart disease, cardiac arrhythmias requiring medication, or a history of a clinically significant electrocardiogram abnormality that, in the investigator's opinion, contraindicates participation in this study Subject has evidence or history of any ischemic vascular diseases including: ischemic heart disease, ischemic abdominal syndromes, peripheral vascular disease or Raynaud's Syndrome, or signs/symptoms consistent with any of the above Subject has evidence or history of central nervous system pathology including stroke and/or transient ischemic attacks (TIAs), epilepsy or structural brain lesions which lower the convulsive threshold; or has been treated with an antiepileptic drug for seizure control within 5 years prior to screening Subject has a history of impaired hepatic or renal function that, in the investigator's opinion, contraindicates participation in this study Subject has hypersensitivity, allergy, intolerance, or contraindication to the use of any triptan, NSAID or aspirin (including all sumatriptan and naproxen preparations) or has nasal polyps and asthma Subject is currently taking, or has taken in the previous three months, a migraine prophylactic medication containing methysergide or dihydroergotamine; or is taking a medication that is not stabilized (i.e., change of dose within the past 2 months) for either chronic or intermittent migraine prophylaxis or for a co-morbid condition that is not stabilized